JW Group and US CureAI Collaborate on Innovative Cancer Cell Therapy and Small Molecule Drug Research

Park Chan-hee, Chief Technology Officer of JW Group (left), and David Ward, CEO of CureAI Therapeutics, are posing for a commemorative photo after signing a joint research agreement.
[Photo by JW Group]

[Asia Economy Reporter Lee Gwan-joo] JW Group announced on the 1st that it has signed a joint research agreement with the U.S. bio venture company CureAI Therapeutics to develop innovative anticancer drugs based on artificial intelligence (AI).

Under this agreement, JW Pharmaceutical and JW Creagen will utilize CureAI's AI and machine learning-based cancer patient genome analysis and biomarker discovery platform to initiate research and development of three anticancer drug projects.

First, JW Pharmaceutical will collaborate with CureAI to discover new small molecule anticancer drug projects targeting immune checkpoint inhibitor-resistant solid tumor patients. They will also establish translational clinical strategies to increase the clinical success rate of anticancer drug candidates developed by JW Pharmaceutical.

JW Creagen, the research corporation of JW New Drug, will cooperate with CureAI to derive new chimeric antigen receptor (CAR)-NK cell therapy candidates for solid tumor treatment. Along with the ongoing development of dendritic cell therapies and CAR-macrophage therapies, they plan to expand their immunocellular therapy drug pipeline.

David Ward, CEO of CureAI, said, “We are very excited to promote an innovative joint research project with JW Group, which has competitiveness in patient-tailored drug development,” and added, “We will strengthen cooperation to bear fruit in next-generation drug development for precision cancer treatment.”

Park Chan-hee, Chief Technology Officer (CTO) of JW Group, stated, “Through joint research with CureAI, which possesses a global-level AI platform for translational clinical research of anticancer drugs, we will expand our drug pipeline,” and added, “We plan to further expand joint research with overseas companies that have specialized innovative R&D platforms.”